1-4 of 4
Aimery de Gramont
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

Julien Taieb, Valérie Taly, Julie Henriques, Camille Bourreau, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Christophe Louvet, Céline Lepere, May Mabro, Joëlle Egreteau, Olivier Bouche, Claire Mulot, Katia Hormigos, Kariman Chaba, Thibault Mazard, Aimery de Gramont, Dewi Vernerey, Thierry André, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5638–5646.
https://doi.org/10.1158/1078-0432.CCR-21-0271
Published: 15 October 2021
View articletitled, Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial
Open the PDF for Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial in another window
Includes: Supplementary data
Journal Articles

Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status

Paul Mésange, Anaïs Bouygues, Nathalie Ferrand, Michèle Sabbah, Alexandre E. Escargueil, Ariel Savina, Benoist Chibaudel, Christophe Tournigand, Thierry André, Aimery de Gramont, Annette K. Larsen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2548–2558.
https://doi.org/10.1158/1078-0432.CCR-17-3187
Published: 31 May 2018
View articletitled, Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
Open the PDF for Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status in another window
Includes: Supplementary data
Journal Articles

Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy

Aziz Zaanan, Jean-François Fléjou, Jean-François Emile, Guetz Gaëtan Des, Peggy Cuilliere-Dartigues, David Malka, Cédric Lecaille, Pierre Validire, Christophe Louvet, Philippe Rougier, Aimery de Gramont, Franck Bonnetain, Françoise Praz, Julien Taïeb
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7470–7478.
https://doi.org/10.1158/1078-0432.CCR-11-1048
Published: 30 November 2011
View articletitled, Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
Open the PDF for Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy in another window
Includes: Supplementary data
Journal Articles

EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies

Virginie Poindessous, Djamila Ouaret, Karima El Ouadrani, Aude Battistella, Virginie F. Mégalophonos, Nyam Kamsu-Kom, Amélie Petitprez, Alexandre E. Escargueil, Pascaline Boudou, Sylvie Dumont, Pascale Cervera, Jean-François Fléjou, Thierry André, Christophe Tournigand, Benoist Chibaudel, Aimery de Gramont, Annette K. Larsen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6522–6530.
https://doi.org/10.1158/1078-0432.CCR-11-1607
Published: 14 October 2011
View articletitled, EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
Open the PDF for EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies in another window